You are here

Preclinical Development of 2nd Generation HIV Maturation Inhibitors

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM132683-01A1
Agency Tracking Number: R41GM132683
Amount: $171,475.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 400
Solicitation Number: PA17-303
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-01
Award End Date (Contract End Date): 2019-08-31
Small Business Information
19008 OXCART PL
Gaithersburg, MD 20886-3148
United States
DUNS: 078653286
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CARL WILD
 (301) 461-4231
 cwild@aol.com
Business Contact
 CARL WILD
Phone: (301) 461-4231
Email: cwild@dfhpharma.com
Research Institution
 SOUTH DAKOTA STATE UNIVERSITY
 
BOX 2201, SAD 200
BROOKINGS, SD 57007-0001
United States

 Nonprofit college or university
Abstract

Project SummaryDespite advances in the development of HIV drugs there remains a need for
new therapiesToxicities associated with long term use of many of the approved HIV drugs
coupled with the development of resistance drives the need for new and novel antiviralsMaturation inhibitorsMIsrepresent one such class of HIV therapiesHIV maturation inhibitors
block virus replication by disrupting the conversion of the capsid precursor proteinCA SPpto the mature form of capsidCApresulting in the formation and release of noninfectious viral particlesUnlike protease inhibitors that bind to and inhibit the action of the viral
proteaseMIs directly target the HIVGag proteinThis novel mechanism of action allows MIs
to retain full activity against viruses that have developed resistance to approved classes of HIV
drugsClinical proof of concept for maturation inhibitors was established with the first in class
MIbevirimatBVMIn a series of trialsBVM was shown to be safe and effective in reducing
HIV viral load in infected individualshowevera lack of uniform patient response was also
observedAnalysis of patient virus revealed that a single amino acid polymorphism in the SPregion of the viral Gag protein was a primary determinant of patient responseThis
polymorphism involves a Val to Ala change at SPamino acidV AApproximatelyof
HIVisolates contain Vand are highly sensitive to BVM while the remainingcontain Aand lack sensitivityAs a result of this observationclinical development of BVM was terminatedDFH Pharmaandapos s current efforts focus on the identification of next generation MIs with broad antiHIV activitySpecificallywe have identifiednd generation MIs that exhibit potent activity
against a range of HIV isolatesUnlike the restricted activity observed with BVMthesend
generation analogs inhibit a broad variety of group M subtypesgroup N and O viruses and
isolates resistant to currently approved HIV drugsRecent testing has determined that the most
potent of these broadly active compounds exhibit ICvalues in the single digit to low double
digit nM rangeThis activity level is within the accepted range for HIV drug development
candidates and compares favorably with the Bristol Myers SquibbBMSMI clinical candidateThe focus of the current application is to build on this success and continue the effort to identifynd generation MIs suitable for development as HIV drugsHaving identified compounds that are
both highly potent and broadly active the objective of the proposed work involves further
characterization of the drug development potential of the most promising compounds to selectnd generation MIs to advance into IND enabling pre clinical studies Project NarrativeDespite advances in the development of HIV drugs there remains a need for
new therapiesMaturation inhibitors represent one class of new HIV therapiesDFH Pharma is
focusing on the characterization and development of a new generation of maturation inhibitors
for use as HIV therapeutics

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government